Ultragenyx Pharmaceutical Inc. buy Bank of America Co.
Start price
31.05.24
/
50%
€37.00
Target price
31.05.25
€70.03
Performance (%)
-20.00%
End price
01.06.25
€29.60
Summary
This prediction ended on 01.06.25 with a price of €29.60. The price of Ultragenyx Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -20.00%. Bank_of_America_Co_ has a follow-up prediction for Ultragenyx Pharmaceutical Inc. where he still thinks Ultragenyx Pharmaceutical Inc. is a Buy. Bank_of_America_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -7.371% | -7.371% | -41.460% |
| iShares Core DAX® | -1,86 % | -1,62 % | 0,64 % |
| iShares Nasdaq 100 | -3,32 % | 3,32 % | 32,00 % |
| iShares Nikkei 225® | -2,30 % | 3,44 % | 51,01 % |
| iShares S&P 500 | -1,31 % | 2,44 % | 23,01 % |
Comments by Bank_of_America_Co_ for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Bank of America Co. from $83.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by Bank_of_America_Co_ for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€19.80
02.01.26
02.01.26
€49.31
02.01.27
02.01.27
-3.96%
05.06.26
05.06.26
